Clinical Trials Logo

Nimotuzumab clinical trials

View clinical trials related to Nimotuzumab.

Filter by:
  • None
  • Page 1

NCT ID: NCT06410651 Recruiting - Esophageal Cancer Clinical Trials

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC. The present study is a one-arm trial that seeks to evaluate the efficacy in patients with unresectable ESCC. The study objectives include R0 resection rate, complete pathological response and treatment toxicity, etc. Nimotuzumab is a recombinant humanized monoclonal antibody against EGFR. Its efficacy and safety in patients with esophageal cancer have been confirmed by many studies. The current prospective phase II study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab and S-1 and concurrent radiotherapy for patients who are not sensitive to induction chemo(immuno)therapy.

NCT ID: NCT04664244 Recruiting - Radiotherapy Clinical Trials

Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Start date: December 19, 2020
Phase: Phase 2
Study type: Interventional

Patients with recurrent or metastatic uterine cervical squamous carcinoma have very poor prognosis. For eligible patients, radiotherapy remains the choice, which has the most effective impact on the survival periods. On the hand, anti-angiogenic therapy has been proved to be promising treatment for recurrent or advanced cervical carcinomas. This study aims to discover the objective response of combination therapy with nimotuzumab (an anti-epidermal growth factor receptor [EGFR] IgG1 humanized monoclonal antibody) and radiotherapy in recurrent or metastatic uterine cervical squamous carcinoma in a single-arm, open, phase 2 clinical trial. The primary endpoint is the objective response rate evaluated by imaging methods. The second endpoints are the progression-free survival and overall survival. The treatment toxicity is regarded as one the second endpoint.

NCT ID: NCT04207918 Completed - Esophageal Cancer Clinical Trials

A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Start date: November 14, 2019
Phase: Phase 2
Study type: Interventional

This phase II clinical study is designed to evaluate the 1 year local tumor control rates after the targeted therapy of intensity-modulated radiation therapy synchronized chemotherapy with nimotuzumab combined with S-1 in local advanced esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.

NCT ID: NCT04136600 Recruiting - Gastric Cancer Clinical Trials

EGFR Monoclonal Antibody for Advanced Gastric Cancer

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This study is intended to evaluate efficacy and safety of EGFR monoclonal antibody (Cetuximab/Nimotuzumab) in combination with a chemotherapy in gastric cancer patients with EGFR amplification.

NCT ID: NCT03554889 Not yet recruiting - Advanced Cancer Clinical Trials

Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies. NK also express an activating Fc receptor that mediates antibody-dependent cellular cytotoxicity (ADCC) and production of immune modulatory cytokines in response to antibody-coated targets. Nimotuzumab, an monoclonal antibody against EGFR (epidermal growth factor receptor), may enhance the ADCC effect of NK cell. This study will evaluate the safety of combination of nimotuzumab and NK Cell in treating advanced cancer patients. Blood samples will also be collected for research purposes.